Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Polycythemia Vera · Ulcerative Colitis Chronic Moderate · PTGX

Protagonist Therapeutics

Protagonist Therapeutics, Inc

Protagonist Therapeutics patent portfolio — 33 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
7707 Gateway Blvd, Suite 140, Newark, California 94560, US HQ
2006 Founded
153 Employees
Public company Type
PTGX · NYSE Ticker
Company details
Status
Public
HQ
7707 Gateway Blvd, Suite 140, Newark, California 94560, US
Founded
2006
Employees
153
Programs
13
Drugs
5
Patents
33
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Protagonist Therapeutics patents

33 pharmaceutical patents indexed for Protagonist Therapeutics. 0 expire within 24 months.

Protagonist Therapeutics has 33 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

33 patents

Patent portfolio

  1. US 12269856

    Hepcidin analogues and uses thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12234300

    Conjugated hepcidin mimetics

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12072338

    Pharmaceutical peptides for the treatment of inflammatory diseases

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11939361

    Compositions of peptide inhibitors of Interleukin-23 receptor

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11845808

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11840581

    α4β7 thioether peptide dimer antagonists

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11807674

    Hepcidin analogues and uses thereof

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11753443

    Conjugated hepcidin mimetics

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11472842

    Analogues of hepcidin mimetics with improved in vivo half lives

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11111272

    α4α7 peptide monomer and dimer antagonists

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11041000

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10941183

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10787490

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10729676

    Opioid agonist peptides and uses thereof

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10626146

    α4β7 thioether peptide dimer antagonists

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10501515

    Hepcidin analogues and uses thereof

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10442846

    Hepcidin analogues and uses thereof

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10407468

    Methods for synthesizing α4β7 peptide antagonists

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10301371

    Cyclic monomer and dimer peptides having integrin antagonist activity

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10278957

    Opioid agonist peptides and uses thereof

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10196424

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10059744

    α4β7 thioether peptide dimer antagonists

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10035824

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10030061

    Hepcidin analogues and uses thereof

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10023614

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9822157

    Hepcidin analogues and uses thereof

    Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9809623

    α4β7 peptide monomer and dimer antagonists

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9714270

    a4B7 integrin thioether peptide antagonists

    Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9624268

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9518091

    A4B7 peptide monomer and dimer antagonists

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9273093

    α4β7 peptide dimer antagonists

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Protagonist Therapeutics have?

33 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Protagonist Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.